Omicia Raises $6.8 Million to Accelerate Whole Genome Interpretation
OAKLAND, Calif. --(Business Wire)--
Omicia, Inc., an analytical genome interpretation company, announced today it has closed $6.8 million of Series A financing led by Artis Ventures, to expand its marketing reach and further optimize its big data genomics offerings. Other investors include Acadia Woods Partners, Bay City Capital, Buchanan Investments, and Casdin Capital.
"The support and significant oversubscription by these renowned firms and individuals will allow us to more rapidly execute our business plan to establish our healthcare IT platform, Opal, as the leader for analysis and interpretation of genomic data, whether for research or the clinic," said Mike Aicher, Omicia's CEO.
The pace of clinical genomics -- and personalized medicine in particular -- is accelerating and creating growing demand for fast, easy-to-use, but sophisticated analytical tools. "Clinical genomics is taking off, and we believe Opal offers substantial advantages over competitors," said Stuart Peterson, president and founde of San Francisco-based Artis Ventures. "Top tier medical institutions are using the big data of next-generation sequencing to further distinguish themselves, and Opal is proving to be the optimal platform to achieve this."
Omicia also announced today the appointment of two new members to its board of directors. Tad Buchanan, principal of Buchanan Investments, and William Gerber, MD, with Bay City Capital, will join Mike Aicher, CEO, John Stuelpnagel DVM, chairman and Martin Reese PhD, founder and president.
"These appointments further establish Omicia as the premiere company in genome analytics," said Mike Aicher. "Tad and Bill are seasoned executives and investors who will play a pivotal role in ensuring we fulfill our strategic plan."
About Omicia, Inc.
Based in the San Francisco Bay Area, Omicia develops scalable and fully integrated informatics systems specifically designed to interpret human genome sequences for research and clinical applications. Omicia's Opal platform provides a set of advanced tools allowing clients to analyze genomes on their own or collaboratively without specialized bioinformatics capabilities. Omicia's mission is to help scientists and clinicians better understand the most relevant information from personal genome sequences and their potential medical consequences.
OpalTM, the leading platform for fast, accurate and flexible genome analysis, enables clinicians, researchers and bioinformaticians alike to derive clinically relevant insights from genomic data.
About Artis Ventures
Artis Ventures supports and partners with entrepreneurs who are driven to positively impact their world through disruptive technological innovation. Notable and disruptive companies the firm has backed include YouTube, Nimble (News - Alert) Storage, Practice Fusion, Aruba Networks, Quid and Stem CentRx among many others.
The 5G Primer
Rethinking the Organization: Success Strategies for Hybrid Work
LoRaWAN in Mission Critical Situations